Eaton Vance Management Kintara Therapeutics, Inc. Transaction History

Eaton Vance Management

  • $67.5 Billion
  • Q3 2022

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.14 - $0.5 $1,400 - $5,000
-10,000 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$0.82 - $2.3 $8,200 - $23,000
10,000 New
10,000 $0

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email